ROSEN, EXPERIENCED INVESTOR ADVISOR, encourages Humacyte, Inc. investors to seek legal counsel in the securities class action lawsuit before the important January 17 deadline

New York, New York – (Newsfile Corp. – January 4, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17, 2024, both dates inclusive (the “Class Period”) Important ones January 17, 2025 Lead Plaintiff Deadline.

SO WHAT: If you purchased Humacyte securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Humacyte class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=31305 or call Phillip Kim, Esq. to. For more information, call 866-767-3653 or email cases@rosenlegal.com. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must go to court no later than January 17, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified advisors who have a track record of success in leadership roles. Companies issuing notices often do not have comparable experience, resources, or significant peer recognition. Many of these firms do not actually litigate securities class actions, but are simply middlemen who refer clients or work with law firms that actually litigate the cases. Be smart when choosing your advisor. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. At that time, Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese company. Rosen Law Firm was Ranked No. 1 by the ISS Securities Class action (WA:) Services for the number of securities class action settlements in 2017. The company has ranked in the top 4 every year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone, the company secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named a Titan of Plaintiffs’ Bar by law360. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Humacyte’s facility in Durham, North Carolina failed to adhere to good manufacturing practices, including quality assurance and microbial testing; (2) review of the Biologics License Application (“BLA”) by the Food and Drug Administration (“FDA”) would be delayed while Humacyte corrects these deficiencies; and (3) as a result, there was significant risk to FDA approval of the Acellular Tissue Engineered Vessel (“ATEV”) for the treatment of vascular trauma; and (4) as a result of the foregoing, Defendants’ positive statements about Humacyte’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details came to light, the lawsuit says investors suffered harm.

To join the Humacyte class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=31305 or call Phillip Kim, Esq. to. Call us toll-free at 866-767-3653 or email cases@rosenlegal.com for class action information.

No class has been certified. Until a course is certified, you will not be represented by legal counsel unless you hire one. You can choose a lawyer of your choice. You can also remain an absent course participant at this point and do nothing. An investor’s ability to participate in any potential future recovery is not dependent on serving as lead plaintiff.

For updates, follow us on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https: / /www.facebook.com/rosenlawfirm/.

Lawyer advertising. Previous results do not guarantee a similar result.

—————–

Contact information:

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236071